solid cancer

solid cancer

Solid tumor Oncology A malignancy that forms a discrete tumor mass–eg, CA of brain, breast, prostate, colorectum, kidney; sarcoma; melanoma, in contrast to lymphoproliferative malignancies–eg, leukemia, which may diffusely infiltrate a tissue without forming a mass. See Lymphoproliferative disorder.
References in periodicals archive ?
Unlike solid cancer tumours, blood cancer cannot be surgically cut out, and consequently blood cancer patients have a very different experience to other people with cancer.
The preventive screening test that will cost between Dh2,500 and Dh4,500 could assess solid cancer risk, except that of the brain.
Most solid cancer tumours that have outgrown their blood supply, and are therefore deprived of oxygen, are difficult to treat, and the cells within are capable of spreading rapidly and doing the most damage.
CLS develops and markets heat-induced cancer immunotherapy for gentle and effective treatment of most types of solid cancer tumors.
The report notes that the pharmaceutical industry is making significant research advances in the treatment of solid cancer tumors.
The assessment found a slightly elevated risk for thyroid cancer, breast cancer and all solid cancer for females exposed as infants to the most radiation and a slightly higher risk of leukemia for males exposed as infants.
Such simulations would encompass the large between-person biomarker heterogeneity that might exist for the same type of cancer and would make the model generalizable for any solid cancer that secretes a biomarker into the circulation.
The drug also reduced the risk of being diagnosed with a solid cancer that had already spread by 31%.
They calculated the long-term risk of second cancers from radiotherapy treatment of first solid cancer sites during a follow-up period of 30 years (1978-2007).
They included 647,672 patients who were 5-year cancer survivors and were aged 20 years and older when they were diagnosed with a first primary invasive solid cancer in 1973-2002.
This study is the first to use genetically modified immune cells, in a technique known as adoptive therapy, to cause cancer regression in patients with a solid cancer as opposed to melanoma.
Neuroblastoma, the most common non-brain solid cancer in children, accounts for some 10 percent of pediatric cancers and 10 percent of childhood cancer deaths.